Cornercap Investment Counsel Inc. Sells 33,616 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Cornercap Investment Counsel Inc. decreased its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 52.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,222 shares of the company’s stock after selling 33,616 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Tenaya Therapeutics were worth $58,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after buying an additional 7,000 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Tenaya Therapeutics by 10.5% in the second quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock worth $242,000 after acquiring an additional 7,441 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Tenaya Therapeutics by 27.7% during the second quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock worth $317,000 after purchasing an additional 22,146 shares in the last quarter. Algert Global LLC acquired a new position in shares of Tenaya Therapeutics during the second quarter worth approximately $74,000. Finally, SG Americas Securities LLC bought a new stake in shares of Tenaya Therapeutics during the third quarter valued at approximately $49,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $2.06 on Tuesday. The firm has a market cap of $163.19 million, a P/E ratio of -1.43 and a beta of 2.34. Tenaya Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $7.01. The firm’s 50 day moving average price is $2.01 and its two-hundred day moving average price is $2.92.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. On average, sell-side analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TNYA has been the topic of several research reports. Chardan Capital reduced their price objective on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a report on Friday, October 18th. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $14.75.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.